🇺🇸 FDA
Pipeline program

Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]

IRB 2240400

Approved small_molecule active

Quick answer

Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] for HEPATITIS C (HCV) is a Approved program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
HEPATITIS C (HCV)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials